C Diff Drug Development

Clostridioides difficile infection is one of the leading causes of antibiotic-associated infectious diarrhea, and is associated with increased incidence and severity worldwide. While antibiotics have traditionally been used for prophylaxis and treatment of C. difficile infection, elevated antibiotic …

Rising incidences and mortalities have drawn attention to Clostridioides difficile infections (CDIs) in recent years. The main virulence factors of this bacterium are the exotoxins TcdA and TcdB, which glucosylate Rho-GTPases and thereby inhibit Rho/actin-mediated processes in cells. This res …

Destiny Pharma plc ("Destiny Pharma" or "the Company") World leading C. difficile scientists to present landmark data on the ability of NTCD-M3 to colonise the gut after antibiotic administration Brighton, United Kingdom – 12 May 2022 – Destiny Pharma (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that

GuruFocus Article or News written by Business Wire and the topic is about:

A novel antibiotic therapy for Clostridioides difficile infection, currently dubbed CRS3123, has demonstrated narrower selectivity and reduced bacterial derangement in the gut compared with other antibiotics.

Researchers have found that viruses called 'bacteriophages' are able to destroy the problematic Clostridium difficile bacterium and could lead to new treatment methods.

Exercise reduces inflammation, fatigue, and aids overall health. Additionally, physical fitness has been associated with desirable changes in the community composition of the athlete gut microbiome, with health-associated taxa being shown to be increased in active individuals. Here, using a combinat …

Clostridioides difficile (C. difficile) infection is associated with high morbidity and mortality. This study aimed to evaluate the protective effect of Lactiplantibacillus plantarum E51 (L. plantarum E51) on C. difficile infection using the Caco-2 monolayer in vitro model. Caco-2 cells were infecte …

The U.S. Food and Drug Administration (FDA) has removed the clinical hold on Finch Therapeutics Group (NASDAQ: FNCH) investigational new drug (IND) application for CP101 in  the prevention of recurrent C. difficile infection (CDI).

Adiso Therapeutics, Inc., a clinical-stage biotechnology company committed to creating medicines that treat inflammatory diseases and improve the lives of patients and their families, today announced the completion of patient enrollment in the Phase 1b clinical study evaluating ADS024, an orally delivered single strain live biotherapeutic product (SS-LBP), for the prevention of C. difficile infection (CDI) recurrence.

Adjuvant chemotherapy and colorectal anastomosis leakage increase risk of Clostridium difficile infection. Patients with Clostridium difficile infection also ha

Finch Therapeutics has slashed its headcount by 20% in order to free funds to focus its resources on its programs in recurrent C. difficile infection and autism spectrum disorder

Lumen Bioscience today announced clinical development progress for LMN-201, an investigational orally delivered cocktail to treat and prevent C. difficile infection (CDI).

SOMERVILLE, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics” or “Company”) (Nasdaq: FNCH), a...

Manipulation of the gut microbiota via fecal microbiota transplantation (FMT) has shown clinical promise in diseases such as recurrent Clostridioides difficile infection (rCDI). However, the variable nature of this approach makes it challenging to describe the relationship between fecal strain colon …

The ability of the anaerobic gastrointestinal pathogen Clostridioides difficile to survive outside the host relies on the formation of dormant endospores. Spore formation is contingent on the activation of a conserved transcription factor, Spo0A, by phosphorylation. Multiple kinases and phosphatases …

Researchers at Harvard University and the Massachusetts Institute of Technology have created a type of bacteria that could potentially protect humans from the harmful side effects of antibiotics, according to a new study published in the journal Nature Biomedical Engineering.

BOSTON, April 13, 2022--PureTech Founded Entity Vedanta Biosciences announced the publication in the journal Cell Host & Microbe of the results from a study for VE303

/PRNewswire/ -- Adiso Therapeutics, Inc., a clinical-stage biotechnology company developing novel medicines targeting chronic inflammatory diseases, today...

Antibiotic-induced alterations in the gut microbiota are implicated in many metabolic and inflammatory diseases, increase the risk of secondary infections and contribute to the emergence of antimicrobial resistance. Here we report the design and in vivo performance of an engineered strain of Lactoco …

Clostridioides difficile bacteria can cause life-threatening diarrhea and colitis owing to limited treatment options and unacceptably high recurrence rates among infected patients. This necessitates the development of alternative routes for C. difficile treatment. Drug repurposing with new indicatio …

Spirulina has been converted into a biomanufacturing platform that offers a way to rapidly produce mass quantities of biologic drugs for common diseases that currently lack effective treatments, say US developers.

Manchmal begünstigen Antibiotika die Entstehung einer potenziell tödlichen Durchfallerkrankung. Statt die verursachenden Keime mit weiteren Antibiotika zu töten, haben Ärzte einen anderen Weg gefunden, die Übeltäter in Schach zu halten.

Learn about our technology, resources, and clinician & patient participation in clinical trials.

The second part of the Phase II clinical trial of DNV3837 in Clostridioides difficile infections to be extended to Canada The extension of the clinical...

A month after another setback in its plans to treat ulcerative colitis, Seres Therapeutics quietly disclosed it will not move forward with a Phase Ib trial. The move, disclosed in an SEC filing Wednesday, puts Seres in a predicament as the Cambridge, MA biotech failed with one potential UC drug,

Background Effective treatment options for recurrent Clostridioides difficile infection (rCDI) are limited, with high recurrence rates associated with the current standard of care. Herein we report results from an open-label Phase 2 trial to evaluate the safety, efficacy, and durability of RBX2660—a standardized microbiota-based investigational live biotherapeutic—and a closely-matched historical control cohort. Methods This prospective, multicenter, open-label Phase 2 study enrolled patients who had experienced either ≥ 2 recurrences of CDI, treated by standard-of-care antibiotic therapy, after a primary CDI episode, or ≥ 2 episodes of severe CDI requiring hospitalization. Participants received up to 2 doses of RBX2660 rectally administered with doses 7 days apart. Treatment success was defined as the absence of CDI diarrhea without the need for retreatment for 8 weeks after completing study treatment. A historical control group with matched inclusion and exclusion criteria was identified from a retrospective chart review of participants treated with standard-of-care antibiotics for recurrent CDI who matched key criteria for the study. The primary objective was to compare treatment success of RBX2660 to the historical control group. A key secondary outcome was the safety profile of RBX2660, including adverse events and CDI occurrence through 24 months after treatment. In addition, fecal samples from RBX2660-treated participants were sequenced to evaluate microbiome composition and functional changes from before to after treatment. Results In this Phase 2 open-label clinical trial, RBX2660 demonstrated a 78.9% (112/142) treatment success rate compared to a 30.7% (23/75) for the historical control group (p